Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR228810 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dose 1 IV infusion |
| Cohort 2 | EXPERIMENTAL | Dose 2 IV infusion |
| Cohort 3 | EXPERIMENTAL | Dose 3 IV infusion |
| Cohort 4 | EXPERIMENTAL | Dose 4 IV infusion |
| Cohort 5 | EXPERIMENTAL | Dose 1 SC injection |
| Cohort 6 | EXPERIMENTAL | Dose 2 SC injection |
| Name | Type | Description |
|---|---|---|
| SAR228810 | DRUG | Pharmaceutical form:solution Route of administration: intravenous |
Inclusion criteria: * Male or female patients with mild to moderate Alzheimer's disease, aged between 50 and 85 years inclusive * Meets criteria for probable Alzheimer's of the National Institute of Neurologic and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Associ...
Top 20 of 24 competitors
SAR228810 is an investigational small molecule being developed for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under study to evaluate its safety and pharmacokinetic profile in patients.
SAR228810 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical research on this drug candidate for Alzheimer's Disease, with the drug currently in Phase 1 development.
SAR228810 is in Phase 1 clinical development. This is the earliest stage of human testing, focused primarily on assessing the drug's safety, tolerability, and how it is absorbed and processed by the body. The drug is investigational and has not yet been approved for any use.
SAR228810 has been studied in one completed clinical trial registered under the identifier NCT01485302. This was a single and repeated dosing study designed to assess the safety and concentration-time profile of SAR228810 in patients with Alzheimer's Disease. The trial enrolled 48 participants across multiple countries.
Yes, the completed Phase 1 trial of SAR228810 was a randomized, double-blind, controlled study. This design means participants were randomly assigned to receive either the drug or a control, and neither the participants nor the researchers knew who received which treatment during the trial, helping to reduce bias in the results.
The Phase 1 clinical trial of SAR228810 was conducted in multiple countries, including Bulgaria, France, Netherlands, South Africa, and Sweden. The study enrolled 48 participants, all of whom were patients with Alzheimer's Disease aged 50 years or older. The trial has been completed.